Interactions between cosmegen(dactinomycin) and Samarium sm 153 lexidronam (samarium sm 153 lexidronam)
dactinomycin and samarium sm 153 lexidronam (Major Drug-Drug)
MANAGEMENT: The manufacturer of samarium recommends against coadministration of these drugs unless benefit outweighs risk. Samarium should not be given after antineoplastics until there has been time for adequate bone marrow recovery.





